MediBeacon® Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in ...

The APPLAUSE-IgAN results demonstrate that targeted, disease-modifying therapy can preserve long-term kidney function.

MediBeacon® Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal functionThe TGFR will be available for sa ...

Investigators assessed markers of chronic kidney disease (CKD) with cancer risks using data from more than one million patients.

Patients with lupus nephritis who received hydroxychloroquine demonstrated a significantly lower risk for glomerular ...

Investigators studied IgA nephropathy relapse, its correlation with kidney failure, and risk factors using a prospective cohort.

Objectives: This study aimed to evaluate the effectiveness of value-based care (VBC) interventions in slowing the progression of chronic kidney disease (CKD), as measured by changes in estimated ...

A new study published in the journal of Pediatric Nephrology revealed an U-shaped relationship between serum uric acid levels and cardiovascular risk in children with chronic kidney disease ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

GFR is key marker of kidney function; IgAN is progressive autoimmune kidney disease that leads to kidney failure in many patients 1-3 Fabhalta is first and only approved complement inhibitor for ...

Statistics, and the standard deviation of our tests, mean that if you order a complete metabolic profile, a lipid panel, a ...

Reduced kidney function from chronic kidney disease may undermine the accuracy of blood-based biomarkers used to predict AD outcomes.